In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol and triglycerides in people with difficult-to-treat lipid disorders, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.
One-time CRISPR therapy safely lowers cholesterol and triglycerides in early trial
- Thread starter Educator
- Start date